Micrornas As Novel Diagnostic Biomarkers in Endometriosis Patients: A Systematic Review and Meta-Analysis Publisher Pubmed



Zafari N¹ ; Bahramy A² ; Majidi Zolbin M³ ; Emadi Allahyari S¹ ; Farazi E⁴ ; Hassannejad Z⁵ ; Yekaninejad MS⁶
Source: Expert Review of Molecular Diagnostics Published:2022

Abstract

Objective: To investigate whether miRNAs have a remarkable pooled diagnostic accuracy, sensitivity, and specificity as noninvasive biomarkers to distinguish endometriosis patients from non-endometriosis women. Methods: A comprehensive literature search of PubMed, Embase, and ProQuest was performed through February 21, 2021 to find relevant studies. Two reviewers independently screened each article, and discrepancies were resolved by consensus. Deeks’ funnel plot asymmetry test was performed to assess the publication bias of included studies. The STATA software and RevMan 5.4 were used for data analysis and quality assessment, respectively. Results: The overall quality of the studies was moderate to high. In total 87 datasets were assessed miRNAs’ performance which results in sensitivity: 0.82, specificity: 0.79, DOR: 18, NPV: 0.80, PPV: 0.78, PLR: 3.97, and NLR: 022. We conducted subgroup analyses, which showed panels of miRNAs (DOR: 54) and serum (DOR: 43) as a target tissue was more reliable to utilize as biomarkers. Deeks’ funnel plot showed that there is no publication bias (P-value = 0.25). Conclusions: Panels of miRNAs differentiate endometriosis patients from non-endometriosis women with high sensitivity and specificity; therefore, it has the potential to use as a noninvasive biomarker. © 2021 Informa UK Limited, trading as Taylor & Francis Group.